Sudden or cardiac deaths on ibrutinib based therapy were associated with a prior history of hypertension or cardiac disease and the use of ace-inhibitors at study entry: analysis from the Phase III NCRI FLAIR Trial
Authors
Munir, T.Pitchford, A.
Bloor, Adrian
Broom, A.
Young, M.
Ben, K.
Walewska, R.
Furtado, M.
Preston, G.
Neilson, J. R.
Pemberton, N.
Sidra, G.
Morley, N.
Cwynarski, K.
Schuh, A.
Forconi, F.
Gatto, S.
Paneesha, S.
Fox, C. P.
Howard, D.
Hockaday, A.
Cairns, D.
Jackson, S.
Greatorex, N.
Patten, P. E.
Allsup, D.
Hillmen, P.
Affiliation
Department of Haematology, St James's University Hospital, Leeds, United KingdomIssue Date
2021
Metadata
Show full item recordCitation
Munir T, Pitchford A, Bloor A, Broom A, Young M, Ben K, et al. Sudden or Cardiac Deaths on IbrutinibBased Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413902149.Journal
BloodDOI
10.1182/blood-2021-152167Additional Links
https://dx.doi.org/10.1182/blood-2021-152167Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-152167